OpenEvidence’s Meteoric Rise: AI-Powered Medical Platform Reaches $12 Billion Valuation
In a significant development within the healthcare technology sector, OpenEvidence, an AI-driven medical information platform tailored for healthcare professionals, has successfully secured $250 million in Series D funding. This latest investment round, co-led by Thrive Capital and DST Global, has propelled the company’s valuation to an impressive $12 billion. This marks a substantial increase from its previous valuation of $6 billion during the Series C funding round in October 2025, which was led by GV (formerly Google Ventures). To date, OpenEvidence has amassed a total of $700 million in funding from a diverse group of investors, including Sequoia Capital, Nvidia, Kleiner Perkins, Blackstone, Bond, Craft Ventures, and the Mayo Clinic.
OpenEvidence distinguishes itself by offering a free, ad-supported platform that delivers AI-powered medical information, positioning itself as a modern counterpart to WebMD but specifically designed for medical practitioners. This focus places it in direct competition with other AI-driven healthcare solutions, such as Anthropic’s Claude for Healthcare, which caters to patients, payers, and providers, and OpenAI’s health product, which is more consumer-oriented.
The platform’s growth trajectory has been remarkable. In December 2025 alone, OpenEvidence facilitated 18 million clinical consultations from verified healthcare professionals across the United States. This figure represents a sixfold increase from the 3 million searches per month reported a year prior. Additionally, the company has surpassed $100 million in revenue, underscoring its rapid expansion and the increasing reliance of the medical community on AI-powered tools.
The substantial investment and escalating valuation of OpenEvidence reflect a broader trend in the healthcare industry, where artificial intelligence is increasingly being integrated to enhance medical decision-making and patient care. Investors’ confidence in OpenEvidence suggests a strong belief in the company’s potential to revolutionize the way medical information is accessed and utilized by healthcare professionals.
As OpenEvidence continues to expand its offerings and user base, it is poised to play a pivotal role in the ongoing transformation of the healthcare landscape, demonstrating the profound impact that AI can have in supporting medical practitioners and improving patient outcomes.
